Schrodinger, Inc. (SDGR)
About Schrodinger, Inc.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $255.9M
- Net income
- -$103.3M
- Total assets
- $726.2M
- Market cap
- $1.1B
- Gross margin
- 55.7%
- Operating margin
- -65.2%
- Net margin
- -40.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $255.9M
- Cost of revenue
- $113.3M
- Gross profit
- $142.6M
- Operating expenses
- $309.5M
- Operating income
- -$166.9M
- Income tax
- $939.0K
- Net income
- -$103.3M
- EPS (basic)
- $-1.41
- EPS (diluted)
- $-1.41
Balance sheet
- Total assets
- $726.2M
- Current assets
- $519.3M
- Total liabilities
- $362.1M
- Current liabilities
- $189.1M
- Shareholders’ equity
- $364.1M
Cash flow
- Operating cash flow
- $13.9M
- Investing cash flow
- $57.9M
- Financing cash flow
- $2.9M
- Net cash flow
- $74.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.1B
- EPS (diluted)
- $-1.41
- Shares outstanding
- 71.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 6, 2020
Schrodinger, Inc. (SDGR) Stock Price
- Reported a net loss of $103.3M in FY2025.
- Revenue grew 86% from FY2021 to FY2025.
- Gross margin of 55.7%, net margin -40.4%.
- Trading 35% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Schrodinger, Inc..
Write a review
News about Schrodinger, Inc.
News & sentiment via Polygon.io
Schrodinger, Inc.: frequently asked questions
Is Schrodinger, Inc. an American company?
Schrodinger, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Schrodinger, Inc. headquartered?
Schrodinger, Inc. is headquartered in New York, New York, United States.
Is Schrodinger, Inc. publicly traded?
Yes — Schrodinger, Inc. is a publicly traded company. Its stock trades under the ticker symbol SDGR on the NASDAQ.
What does Schrodinger, Inc. do?
Schrodinger, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
